How much funding has Antheia, Inc. raised?

Antheia, Inc. has raised $228.0M in total funding, most recently a Series C round.

Who are Antheia, Inc.'s investors?

Antheia, Inc.'s investors include Global Health Investment Corporation, Viking Global, Khosla Ventures, EDBI, Mayfield Fund, Peak XV Partners.

When was Antheia, Inc. founded?

Antheia, Inc. was founded in 2016.

Where is Antheia, Inc. headquartered?

Antheia, Inc. is headquartered in Menlo Park, California, United States.

What industry is Antheia, Inc. in?

Antheia, Inc. operates in Biotech, Healthcare.

How many employees does Antheia, Inc. have?

Antheia, Inc. has 1-10 employees.

Antheia, Inc.

Ending drug shortages with advanced biosynthesis

Menlo Park, United States · Founded 2016 · $228.0M raised

Biotech

Healthcare

Headquarters: Menlo Park, California
Employees: 1–10
Founded: 2016
Business Model: B2B

Website: antheia.bio
Total Funding: $228.0M
Last Round: $24.0M Series CJan 2026
Rounds: 4

About

Antheia, Inc. is a next-generation pharmaceutical ingredient manufacturer using synthetic biology and advanced biosynthesis to produce Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) for essential medicines. Founded by Stanford synthetic biology pioneer Dr. Christina Smolke, Antheia engineers yeast to reconstruct complex plant biosynthetic pathways—converting simple sugars into high-value pharmaceutical compounds at commercial scale via fermentation. The company has a pipeline of 70+ biosynthetic KSMs and APIs and achieved commercial-scale shipment of thebaine for use in Narcan (naloxone) production, addressing critical drug shortage vulnerabilities in the U.S. pharmaceutical supply chain.

Summary

Antheia, Inc. is a Biotech company based in Menlo Park, United States, founded in 2016. It has raised $228.0M in total across 4 rounds, most recently a $24.0M Series C round in Jan 2026. Investors include Global Health Investment Corporation, Viking Global and Khosla Ventures.

LinkedIn X (Twitter)